Schott Pharma stock holds steady as investors await next earnings update
Published on 08/21/2026 at 13:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Schott Pharma AG & Co. KGaA (ISIN DE000A3ENQ51) stock most recently traded at EUR 22.05 as of August 20, 2026 in a real-time quote, showing a flat performance on the day and no year-to-date change at that level per current market data. The price context comes from a calendar and quote overview that lists EUR 22.05 with a 0.00 percent move and 0.00 percent change since the start of the year, indicating a period of consolidation in the shares at this mark. For investors following Schott Pharma, this stable quote sets the stage for the next phase of the company’s earnings and guidance narrative.
Latest trading snapshot and valuation context
Per the latest calendar-based quote entry dated August 20, 2026, Schott Pharma stock is shown at a level of EUR 22.05 with a daily percentage change of 0.00 percent, suggesting that the most recent completed trading session did not bring a new directional move at this price point. The same snapshot lists the change since January 1, 2026 at 0.00 percent, meaning that at EUR 22.05 the shares are aligned with their starting reference level for the year according to this specific data view. This flat performance profile contrasts sharply with many pharmaceutical and biotech peers that have logged double-digit moves during 2026, underscoring the relatively muted volatility seen in Schott Pharma over this period.
While the available quote summary does not break out market capitalization directly, the EUR 22.05 price can be set against the company’s free-float structure to derive an implied equity valuation. If Schott Pharma maintains a share count in the hundreds of millions, a price in the EUR 22 region would naturally place the firm well into the multi-billion-euro market cap bracket, giving it meaningful scale within the European healthcare and pharmaceutical equipment segment. By comparison, a separate earnings call from another pharma issuer highlighted cash balances in the EUR 800 million range and equity of EUR 1.4 billion, which would translate to a smaller capitalization than Schott Pharma at EUR 22.05 if Schott’s share base is larger. This juxtaposition helps frame Schott Pharma’s potential size advantage and strategic positioning.
Earnings, guidance and growth backdrop
For fundamental context, investors look beyond the latest price to the most recent interim and full-year figures that Schott Pharma has disclosed in its investor communications. The fresh reporting window relevant to August 21, 2026 includes the latest half-year or second-quarter 2026 results, where companies in the broader pharma and life sciences space have reported revenue growth rates exceeding 20 percent and net profit increases north of 30 percent compared with the prior-year period. One example from the sector showed first-half 2026 revenue of CNY 4.58 billion, up 27.8 percent year over year, and net profit attributable to equity holders of CNY 830 million, up 37.9 percent, along with adjusted net profit rising 48.7 percent. That trajectory illustrates what investors might anticipate from high-growth pharma names and serves as a reference point when evaluating Schott Pharma’s own latest numbers and guidance.
Some peers have also reported detailed operating metrics such as total product revenue, operating profit margins, and non-IFRS net profit in their Q2 2026 results, highlighting, for instance, EUR 315 million in total product revenue with a 105 percent year-over-year increase and operating profit margins reaching 65 percent in the quarter. Non-IFRS operating margins at 27 percent and net profit of EUR 207 million for Q2 2026 underscore the potential profitability that can be achieved when product portfolios scale. These figures, though belonging to another pharma issuer, provide a benchmark for how investors may frame Schott Pharma’s profitability ambitions as the company continues to expand its injectable drug containment and delivery solutions business globally.
Guidance communication has likewise become central to the sector’s valuation story. When a pharma company signals high-20-percent revenue growth and strong margin expansion for the current year, the market often prices in substantial upside potential relative to consensus. For Schott Pharma, the most recent investor guidance would focus on parameters such as mid-teens to high-teens percentage growth in revenue for fiscal 2026, improving EBIT margins driven by operating leverage, and disciplined investment in capacity and innovation to support long-term demand from biopharma clients. If Schott Pharma’s management targets a revenue increase that matches or surpasses the 27.8 percent growth rate seen in the example peer for the first half of 2026, investors may treat the shares as a growth compounder within the European healthcare universe.
Analyst and consensus perspective
The analyst community frequently benchmarks companies like Schott Pharma against other pharma and life-sciences names that have recently published strong Q2 2026 results. In one prominent case, analysts reviewed a company reporting EUR 339 million in total revenue for Q2 2026, including EUR 24 million in nonproduct collaboration revenue and EUR 17 million in milestone income tied to a key pipeline asset. They noted that blockbuster-level sales of a lead product in its second year post-launch supported non-IFRS net profit of EUR 61 million and a robust cash balance of EUR 812 million. Such figures often translate into forward-looking price targets that emphasize sustainable double-digit growth and solid balance sheets.
For Schott Pharma, consensus expectations for fiscal 2026 and 2027 would similarly revolve around revenue growth in the mid- to high-teens percentage range, supported by rising demand for high-quality pharmaceutical glass and polymer containers for injectable drugs, as well as prefillable syringes and related delivery systems. Analysts might model EBIT margins improving by several percentage points compared with the last reported year as the company benefits from economies of scale and a focus on higher-value solutions for complex biologics. When consensus anticipates this type of margin expansion, the resulting EPS trajectory can justify a valuation multiple that holds Schott Pharma stock in the low- to mid-20s EUR range, particularly if the broader sector trades at comparable earnings multiples.
Product and business model: injectable drug containers
Schott Pharma’s business model centers on engineered glass and polymer containers and delivery systems for injectable pharmaceuticals, a niche where reliability, safety, and compatibility with sensitive biologic formulations are critical. A representative product is its advanced prefillable syringe platform designed for biologics and vaccines, which offers high-quality glass barrels, optimized stoppers and plunger systems, and coatings that minimize interaction between drug and container. These solutions are intended to reduce particle formation, improve shelf-life stability, and make it easier for healthcare providers to administer injections with precision.
The product lineup supports pharma companies throughout the drug lifecycle, from clinical development to large-scale commercial production. For instance, Schott Pharma’s prefillable syringes and vials are used in filling lines that can handle tens of thousands of units per hour, enabling contract manufacturers and biotech firms to meet global demand surges such as those seen during vaccination campaigns. The firm also invests in innovations like ready-to-use containers, where vials and syringes are sterilized and packaged to streamline pharmaceutical filling operations and reduce contamination risk. These offerings align with industry trends toward greater automation, quality control, and supply-chain resilience.
Closing view on Schott Pharma stock
Looking at the latest quote data, Schott Pharma stock at EUR 22.05 as of August 20, 2026 reflects a phase of stability compared with more volatile sector peers, with the same snapshot showing a 0.00 percent daily move and 0.00 percent change relative to the January 1, 2026 reference level. For investors, that steadiness serves as both a sign of consolidation and a reminder that the next earnings release and any fresh guidance update may be important catalysts for a re-rating. As Schott Pharma continues to build out its injectable drug container and delivery solutions portfolio and aligns its financial performance with sector benchmarks for revenue growth and margin expansion, the EUR 22.05 price level will be watched closely as a potential base for future advances in the shares.
